Ustekinumab as Induction and Maintenance Therapy for Crohn’s Disease

著者: Brian G. Feagan, William J. Sandborn, Christopher Gasink, Douglas Jacobstein, Yinghua Lang, Joshua R. Friedman, Marion Blank, Jewel Johanns, Long-Long Gao, Miao Ye, Omoniyi J. Adedokun, Bruce E. Sands, Stephen B. Hanauer, Séverine Vermeire, Stephan R. Targan, Subrata Ghosh, Willem J. de Villiers, Jean–Frédéric Colombel, Zsolt Tulassay, Ursula Seidler, Bruce Salzberg, Pierre Desreumaux, Scott D. Lee, Edward V. Loftus, Levinus A. Dieleman, Seymour Katz, Paul Rutgeerts - New England Journal of Medicine, NEJM 2016 被引用: 1,806

Ustekinumab, a monoclonal antibody to the p40 subunit of interleukin-12 and interleukin-23, was evaluated as an intravenous induction therapy in two populations with moderately to severely active Crohn's disease. Ustekinumab was also evaluated as subcutaneous maintenance therapy.